Member Info for Burble

Charlesrixon.

May I add to Chester's post. For context, I hold a PhD which focussed on the development of antibody therapeutics for melanoma and cervical cancer and still work within the cancer research sector.

Scancell's pipeline is different to other biotechs and is strengthened by the fact that we are not specifically talking about individual products (think individual antibodies, or small-molecule therapeutics). We are talking about adaptable platforms.

Immunobody is a DNA based platform which has the ability to produce high-avidity T-cells to kill infected/cancer cells. Being a DNA based platform it is easy to produce a range of products from - so within a relatively short time a new Immunobody construct targetting a different cancer target or infectious disease target could be generated. Furthermore, the cost of DNA production is small and the product has high stability and a long shelf life meaning high profit margins/low costs.

Moditope is slightly different, but again is a platform based product - this time targetting stress-inducted post-translational modification produced by cancer cells. This has the potential to have low off-target side effects and also target large numbers of cancers.

Avidimab is another product and platform, which can be used to enhance antibodies and their direct cell killing efficiency. This means it can be added to any antibody currently on the market and in development which could improve their effectiveness. This could be licenced to any number of pharma companies developing antibody therapeutics.

Add to all of that we have the anti-glycan monoclonal antibodies. These are more stand along products on their own and have specific functions/targets for each one. These could be valuable as single entity products or as a package.

As a pipeline, what stands out for Scancell vs. other pharma/biotech startups is the fact that the bulk of their products are platforms. This means they have almost infinite scope to generate new therapies once the platform is proved to work. So whilst there is risk with any product and platforms are no different, once one of these makes it through trials to the clinic, the platform is validated and so any number of 'flavours' of that platform, targetting any number of targets becomes available. Covidity validates Immunobody and Avidimab and a new needle-free delivery system in a single set of trials. SCIB1 trials validates immunobody in cancer and the new Moditope trial (esp. phase 2) is 4 hard to treat cancer trials in one.

If you compare this to a lot of biotechs/pharma they put all their eggs in a single basket with a single product. If that fails, it's back to the drawing board. If it works, many companies will buy that product and incorporate it into their own portfolio. Scancell platforms if validated could be v.v.valuable especially if licenced out to any number of players in the field of infectious disease or oncology.

WF

Agree with this. Add to that, if the non-injectable route is validated it adds to the value of our vaccines considerably. Especially if the storage and shelf life is consistent with what we already know about the DNA based vaccine.

From the Independent on this, they have said the following 'antibody levels against Covid-19 in fully vaccinated people were found to wane over the course of more than 300 days, while T-cells – which seek out and kill infected cells within the body – also dropped off after 182 days, the Oxford study showed.'

I believe Lindy has previously said that Immunobody generates a potent and enduring T-cell response. So hopefully this bodes well for SCov1 and SCov2

Bermuda,

You’re right they do, but unless my memory is failing me, often presentations only have the timeline of patients diagram from the initial SCIB1 trial. Either way, an enhanced/updated PR strategy can never go amiss.

AB

IMHO, day to day fluctuations with the share price are immaterial when you are a LTH and see the end goal. For me, the longer it stays at this level the better because it means I can keep adding to my holdings. I think that a lot of covid shares benefitted early on in the pandemic, but the mood of the market seems to have gone elsewhere. I suspect SCLP is flying under the radar a bit, but judging from news coming out across the world Covid hasn't gone away and with the rise of the Delta (and newly found Lambda) strain, I think we will be in the right place at the right time.

My previous comments were more focussed on the general PR strategy long term - not specifically saying that we should be banging the drum at each and every announcement. It was more a comment that as humans, we naturally like visuals especially if they are real life photographs/scans, if you say 'a tumour has regressed by 25%' that means little to a lot of people. If you show a CT scan of a large lung met and then you show that same patient a few months later after treatment with that shrinking or gone, it makes a lot of people sit up and think 'wow, that treatment seems to be working in that patient'.

If you look at SCLP, they publish these things in research papers, but so few people will read those properly and also understand them. Showing more of the real world CT scans of a patients or mice etc to go alongside diagrams and ******-meier survival plots I think would get people more engaged with the science. Do that repeatedly and it starts to solidify people's belief that SCLP is onto something with platforms which have the potential to be revolutionary here.

This type of publicity is what Scancell are missing.

Whilst photos like these are graphic, they sadly do reflect the reality that is faced by many patients being treated with these therapies. Photos like these really demonstrate to outsiders just how good products can be when they work.

I would love to see this type of publication for Modi-1 and SCIB1 trials alongside diagrams. But this would hit home how good both the Immunobody platform and a moditope are a real world patient in the clinic.

Interesting! Shall have a gander at what there is out there. Equally as good if similar technology is already in use.

Max,

It’s even more exciting when you realise this isn’t the only feather in Scancell cap! Especially as we could have an update on SCIB1 melanoma trial, Modi-1 trial, monoclonal antibodies or knowing Lindy, something new and left field.

If it were a nasal spray inhalable drug that would be an absolute game changer world wide, not just for Covidity but for the whole immunobody platform.

Imagine, doctor finds you have cancer with XYZ target antigen. Take a quick puff of this inhaled drug and let your T-cells get to work!

CEPI evaluation methods.

'All the vaccine candidates we invest in were identified as promising by in-house and external expert reviewers. The progress of these candidates is actively assessed on a regular basis as data comes in.

Ultimately, however, decisions on whether to authorise a vaccine, or to make it available for emergency use, lie with the stringent and independent national regulatory authorities. Their reviews are based on data from clinical trials supported with CEPI investments. But, while we are not directly involved in this, we have created a system to reliably assess immunological responses generated by our vaccine candidates and others in development.

We have a network of nine laboratories all over the world spanning Europe, Asia, North America and Latin America. They all follow the same standardised protocols and use the same tests to evaluate samples from participating vaccine developers. This removes much of the variability and allow for head-to-head comparisons of the immune responses induced by multiple vaccine candidates.'

From the article posted last week - https://sciencemediahub.eu/2021/06/16/a-scientists-opinion-interview-with-dr-frederik-kristensen-about-the-coalition-for-epidemic-preparedness-innovations-cepi/

Now, I'm curious as to whether LD et al. have already submitted Covidity to CEPI for evaluation, even as far back as the original universal blog post which mentioned us back in March. That would give three months at least worth of data from these labs if the construct was finalised back in January as per the interim results RNS.

From the Scancell website

Akua joined Scancell in 2020 to implement the Company’s Quality Management System, ensuring that trial participants and data are safeguarded in compliance with global regulatory requirements. She has nearly 20 years of operational experience within contract research organisations, pharmaceutical and biotech businesses, including Gilead Sciences and Bionical Emas.

The excitement continues to build!

This makes me wonder whether there are ongoing discussions with collaborators/Pharma which are happening behind closed doors.

Some interesting things on Stifel’s website.

‘Stifel Europe’s growth has focused on building a Trans-Atlantic debt and equity powerhouse concentrated in small and mid cap companies for institutional investors.’

‘Offering institutional investors differentiated, research-driven equity products with a dedication to value and service.’

Anybody got any ideas what this could be about?

https://www.dailymail.co.uk/health/article-9655627/Breakthroughs-including-drug-cure-kidney-cancer-unveiled-worlds-biggest-cancer-conference.html

As much as I loath the DM, this article is interesting. Especially the section on cancer vaccines and training the immune system. This quote is of interest ‘ nes will be the next big development in fighting cancer and will eventually make the immunotherapies we’re talking about now irrelevant.’

Scancell. Ahead of the curve again.

Just got an email notification to say that the first patient has been dosed with a CAR-T therapy for NY-ESO-1 in patients with unresectable, metastatic or recurrent synovial sarcoma. This is a GSK clinical trial.

The interesting thing with this is that CAR-T treatments are expensive and patient specific as autologous T-cell transfers are required. Plus after T-cell harvest, they have to go through multiple handling steps in the labs before reinfusion back into the patient. SCIB2 on the other hand is an off the shelf DNA based vaccine which basically does what a CAR-T therapy does outside the body, but inside the body.

It will be both interesting to see how this GSK progresses (whether the target is good with a good safety and target profile) and whether we see SCIB2 progressing.

Oh and also add to that the dispatch notice number 11689.

I ordered a three pack last week. They arrived relatively quickly and are super comfortable. Would highly recommend to others, they're comfortable for all day usage.

Anyway details are as follows:
Order number #2922562340 (placed 03/05/2021).

Bermuda,

Thank you, this was what I suspected. that patient's were only followed for a set period of time. Just peaked my interest to know whether they were still alive today. We have seen patients treated with early iterations of Immunobody surviving long term - 12 years or more in some cases. https://www.dailymail.co.uk/health/article-1278836/Holy-Grail-cancer-vaccine-blasts-tumours-weeks-hailed-huge-leap-fighting-disease.html

Random question - Scancell continue to present data on SCIB1 overall survival. With 14 of 16 resected patients receiving 2-4 mg doses have survived for more than 5 years (February 2018).

Do we know how long the follow-up for these patients is scheduled to be? I'm just curious as we are 8 years down the line whether there is any scope for an update on these patients or whether they were only followed for 5 years post trial.